SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
January 09 2024 - 8:30AM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device
company developing proprietary solutions to reduce the consequences
of hyperinflammation on vital organs, announces the issuance of
U.S. Patent No. 11,866,730 with broad claims directed to methods of
using the Selective Cytopheretic Device (SCD) to treat subjects
with inflammatory conditions and to process activated leukocytes
and platelets. The SCD is a first-in-class, cell-directed
extracorporeal therapy that selectively targets highly active
inflammatory cells to quell the inflammatory response.
“This patent significantly fortifies our
intellectual property portfolio and is highly supportive of our
strategy to validate our technology’s application across multiple
high-value clinical indications in which hyperinflammation plays a
role,” said Eric Schlorff, CEO of SeaStar Medical. “Regardless of
its source, uncontrolled hyperinflammation can lead to vital organ
damage and even death. Our SCD therapy works to selectively target
the most highly activated cells responsible for inflammation to
bring activated cells into a reparative state. This can stop the
potential damage of over-activated cells and potentially reverse
the damage they cause.”
This newly issued patent covers methods for
using SCD cartridges to treat inflammatory conditions by
extracorporeally sequestering activated leukocytes and/or platelets
and inhibiting or deactivating their inflammatory action, as well
as methods for processing activated leukocytes and/or platelets.
Treating inflammatory conditions requires controlling the number of
leukocytes and/or platelets without removing too many cells, which
can harm the healing process. The patent’s claimed methods require
the SCD cartridge to have specific ratios of surface area for
sequestering activated leukocytes and/or platelets to SCD inner
volume.
Unlike pathogen removal and other
blood-purification tools, the SCD selectively targets the most
highly activated proinflammatory neutrophils and monocytes. The
Company has observed that these most highly activated immune cells
are turned off in a low calcium environment. The SCD therapy mimics
nature by creating a unique micro-environment, attracting these
highly activated effector cells and neutralizing them in such an
environment. These cells are then returned to the body through the
blood, signaling the body to focus on repair.
About SeaStar
MedicalSeaStar Medical is a medical technology
company that is redefining how extracorporeal therapies may reduce
the consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to
provide life-saving solutions to critically ill patients. The
Company is developing and commercializing cell-directed
extracorporeal therapies that target the effector cells that drive
systemic inflammation, causing direct tissue damage and secreting a
range of pro-inflammatory cytokines that initiate and propagate
imbalanced immune responses. For more information visit
https://seastarmedical.com/or visit us on LinkedIn or X (formerly
Twitter).
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to the ability of SCD to treat patients
with AKI and other diseases. Words such as “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside SeaStar Medical’s control and are
difficult to predict. Factors that may cause actual future events
to differ materially from the expected results include, but are not
limited to: (i) the risk that SeaStar Medical may not be able to
obtain regulatory approval of its SCD product candidates; (ii) the
risk that SeaStar Medical may not be able to raise sufficient
capital to fund its operations, including clinical trials; (iii)
the risk that SeaStar Medical and its current and future
collaborators are unable to successfully develop and commercialize
its products or services, or experience significant delays in doing
so, including failure to achieve approval of its products by
applicable federal and state regulators, (iv) the risk that SeaStar
Medical may never achieve or sustain profitability; (v) the risk
that SeaStar Medical may not be able to access funding under
existing agreements, including the equity line of credit and
forward purchase agreements; (vi) the risk that third-parties
suppliers and manufacturers are not able to fully and timely meet
their obligations, (vii) the risk of product liability or
regulatory lawsuits or proceedings relating to SeaStar Medical’s
products and services, (viii) the risk that SeaStar Medical is
unable to secure or protect its intellectual property, and (ix)
other risks and uncertainties indicated from time to time in
SeaStar Medical’s Annual Report on Form 10-K, including those under
the “Risk Factors” section therein and in SeaStar Medical’s other
filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:
LHA Investor RelationsJody Cain(310)
691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Apr 2024 to May 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From May 2023 to May 2024